Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer. Tafamidis acts in a similar way to the natural hormone T4, prevents TTR amyloid fibril formation, and offers a potential alternative to liver transplantation for the treatment of patients with TTR familial amyloid polyneuropathies (TTR-FAP).
Keywords: drug discovery; familial amyloid polyneuropathy; ligand design; tafamidis meglumine; transthyretin.
Copyright © 2013 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.